



04-12-07

IPW

Dkt. No. 29248/19

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Erik Buntinx  
Appl. No. : 10/752,423  
Filed : January 6, 2004  
For : METHOD OF TREATING MENTAL DISORDERS USING  
D4 AND 5-HT2A ANTAGONISTS, INVERSE AGONISTS OR  
PARTIAL AGONISTS  
Group Art : 1617  
Examiner : SOROUGH, LAYLA  
Customer No. : 1912

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

"Express Mail" mailing label No. EV 725835141 US  
Date of Deposit: April 11, 2007

I hereby certify that this paper or fee is being  
deposited with the United States Postal Service  
"Express Mail" service under 37 CFR 1.10 on the date  
indicated above and is addressed to the  
Commissioner for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450.

Name: Alan D. Miller


Signature: [Signature]

Sir:

This Supplemental Information Disclosure Statement is being filed to  
supplement the Information Disclosure Statement filed on August 9, 2005 in connection  
with the above-identified application.

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicant  
would like to direct the Examiner's attention to the twenty-one references that are listed  
on enclosed Form PTO/SB/08A-B (2 pages). Copies of the non-patent references were  
previously submitted to the Patent Office during prosecution of U.S. Patent Application

Applicant: Erik Buntinx  
Appl'n. No.: 10/752,423  
Filed: January 6, 2004  
Page 2




No. 10/725,965, from which the subject application claims priority under 35 U.S.C. §120. Accordingly, pursuant to 37 C.F.R. § 1.98(d), copies of previously submitted references are not included with this Information Disclosure Statement. Non-English language Reference numbers 13-15 on the enclosed Forms were cited in an Official Communication issued in patent family member European Patent Application EP 04 025 035.9


Applicant is submitting the subject Supplemental Information Disclosure Statement pursuant to 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Accordingly, no fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required in connection with the submission of this Supplemental Information Disclosure Statement or to maintain the pendency of the subject application, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP  
Attorneys for Applicant  
90 Park Avenue  
New York, New York 10016  
(212) 336-8000

Dated: April 11, 2007  
New York, New York

By   
Alan D. Miller, Reg. No. 42,889



Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

PTO/SB/08A (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

### Complete if Known

Application Number	10/752,423
Filing Date	January 6, 2004
First Named Inventor	Erik Buntinx
Art Unit	1617
Examiner Name	SOROUGH, LAYLA
Attorney Docket Number	29248/19

### U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	1	US- 6,358,698 B1	03-19-2002	Weiner et al.	
	2	US- 2005/0148018 A1	07-07-2005	Weiner et al.	
	3	US- 2004/0213816 A1	10-28-2004	Weiner et al.	
	4	US- 2006/0264465 A1	11-23-2006	Weiner et al.	
	5	US- 2006/0264466 A1	11-23-2006	Weiner et al.	
	6	US- 2006/0199842 A1	09-07-2006	Weiner et al.	
	7	US- 2005/0261340 A1	11-24-2005	Weiner et al.	
	8	US- 2005/0261278 A1	11-24-2005	Weiner et al.	
	9	US- 2005/0288328 A1	12-29-2005	Weiner et al.	
	10	US- 2005/0203130 A1	09-15-2005	Buntinx	
	11	US- 2007/0078162 A1	04-05-2007	Buntinx	
	12	US- 2005/0119253 A1	06-02-2005	Buntinx	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/752,423
				Filing Date	January 6, 2004
				First Named Inventor	Erik Buntinx
				Art Unit	1617
				Examiner Name	SOROUGH, LAYLA
Sheet	2	of	2	Attorney Docket Number	29248/19

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	13	www.biam2.org/www/Sub2783.html, entitled "Pipamperone Dichlorhydrate," November 12, 2000, 1-4.	
	14	www.adiph.org/pic/pedia-neuroleptiques.pdf, entitled "Medicaments Psychotropes: Posologies Chez L'Enfant et L'Adolescent," August 2001, 1-3.	
	15	HEISER P et al., entitled "The selective serotonin reuptake inhibitors and the newer antidepressants in child and adolescent psychiatry," Zeitschrift fur Kinder - und Jugendpsychiatrie und Psychotherapie Switzerland 30: 2002, 173-183.	
	16	CARLIER PR et al., "Synthesis of a Potent Wide-Spectrum Serotonin-, Norepinephrine-, Dopamine- reuptake inhibitor (SNDRI) and a species-selective dopamine reuptake inhibitor based on the gamma-amino alcohol functional group, Bioorgan. Medicin. Chem. Let. 8, 1998, 487-492.	
	17	FITZGERALD K D et al., entitled "Risperidone Augmentation of Serotonin Reuptake Inhibitor Treatment of Pediatric Obsessive Compulsive Disorder," Journal of Child and Adolescent Psychopharmacology, Vol. 9, No. 2, 1999, 115-123.	
	18	MCDUGLE C J et al., entitled "A Double-blind, Placebo-Controlled Study of Risperidone Addition in Serotonin Reuptake Inhibitor-Refractory Obsessive-compulsive Disorder," Arch Gen Psychiatry, Vol. 57, August 2000, 794-801.	
	19	MAINA G et al., entitled "Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued," Int. Clin. Psychopharm, 18, 2003, 23-28.	
	20	HIROSE S et al., entitled "An Open Pilot Study Combining Risperidone and a Selective Serotonin Reuptake Inhibitor as Initial Antidepressant Therapy," J. Clin. Psych. 63, 2002, 733-736.	
	21	Truffinet P et al., Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. Am J. Psychiatry 156: 419-425, 1999.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.